PDF(Pubmed)
Abstract：
UNASSIGNED: Abnormal liver biochemistry (ALB) is common among patients with COVID-19 infection due to various factors. It is uncertain if it persists after the acute infection. We aimed to investigate this.
UNASSIGNED: A multicenter study of adult patients hospitalized for COVID-19 infection, with at least a single abnormal liver function test, was conducted. Detailed laboratory and imaging tests, including transabdominal ultrasound and FibroScan, were performed at assessment and at 6-month follow-up after hospital discharge.
UNASSIGNED: From an initial cohort of 1246 patients who were hospitalized, 731 (58.7%) had ALB. A total of 174/731 patients fulfilled the inclusion criteria with the following characteristics: 48.9% patients had severe COVID-19; 62.1% had chronic liver disease (CLD); and 56.9% had metabolic-associated fatty liver disease (MAFLD). ALB was predominantly of a mixed pattern (67.8%). Among those (55.2%) who had liver injury (aspartate aminotransferase/alanine aminotransferase >3 times the upper limit of normal, or alkaline phosphatase/γ-glutamyl transferase/bilirubin >2 times the upper limit of normal), a mixed pattern was similarly predominant. Approximately 52.3% had normalization of the liver lunction test in the 6-month period post discharge. Patients with persistent ALB had significantly higher mean body mass index (BMI) and serum low-density lipoprotein (LDL), higher rates of MAFLD and CLD, higher mean liver stiffness measurement and continuous attenuated parameter score on FibroScan, and higher rates of liver injury on univariate analysis. Multivariate analysis was not statistically significant.
UNASSIGNED: Approximately 47.7% of COVID-19 patients were found to have persistent ALB up to 6 months following the acute infection, and it was associated with raised BMI, elevated serum LDL, increased rates of MAFLD and CLD, and higher rates of liver injury on univariate analysis, but not on multivariate analysis.
UNASSIGNED: A multicenter study of adult patients hospitalized for COVID-19 infection, with at least a single abnormal liver function test, was conducted. Detailed laboratory and imaging tests, including transabdominal ultrasound and FibroScan, were performed at assessment and at 6-month follow-up after hospital discharge.
UNASSIGNED: From an initial cohort of 1246 patients who were hospitalized, 731 (58.7%) had ALB. A total of 174/731 patients fulfilled the inclusion criteria with the following characteristics: 48.9% patients had severe COVID-19; 62.1% had chronic liver disease (CLD); and 56.9% had metabolic-associated fatty liver disease (MAFLD). ALB was predominantly of a mixed pattern (67.8%). Among those (55.2%) who had liver injury (aspartate aminotransferase/alanine aminotransferase >3 times the upper limit of normal, or alkaline phosphatase/γ-glutamyl transferase/bilirubin >2 times the upper limit of normal), a mixed pattern was similarly predominant. Approximately 52.3% had normalization of the liver lunction test in the 6-month period post discharge. Patients with persistent ALB had significantly higher mean body mass index (BMI) and serum low-density lipoprotein (LDL), higher rates of MAFLD and CLD, higher mean liver stiffness measurement and continuous attenuated parameter score on FibroScan, and higher rates of liver injury on univariate analysis. Multivariate analysis was not statistically significant.
UNASSIGNED: Approximately 47.7% of COVID-19 patients were found to have persistent ALB up to 6 months following the acute infection, and it was associated with raised BMI, elevated serum LDL, increased rates of MAFLD and CLD, and higher rates of liver injury on univariate analysis, but not on multivariate analysis.
摘要：
■由于各种因素，肝脏生化异常（ALB）在COVID-19感染患者中很常见。不确定急性感染后是否持续存在。我们打算对此进行调查。
■一项针对COVID-19感染住院的成年患者的多中心研究，至少有一次肝功能异常检查，进行了。详细的实验室和成像测试，包括经腹超声和FibroScan,在评估时和出院后6个月随访时进行.
■从1246名住院患者的初始队列中，731（58.7%）患有ALB。共有174/731例患者符合纳入标准，具有以下特征：48.9%的患者患有重度COVID-19；62.1%的患者患有慢性肝病（CLD）；56.9%的患者患有代谢相关脂肪肝（MAFLD）。ALB主要为混合模式(67.8%)。在那些有肝损伤（天冬氨酸转氨酶/丙氨酸转氨酶>正常上限的3倍，（55.2％），或碱性磷酸酶/γ-谷氨酰转移酶/胆红素>正常上限的2倍），混合模式同样占主导地位。在出院后的6个月内，约有52.3％的肝脏结合力测试恢复正常。持续性ALB患者的平均体重指数(BMI)和血清低密度脂蛋白(LDL)显著增高,MAFLD和CLD的发生率更高，FibroScan的平均肝脏硬度测量值和连续衰减参数评分更高，单因素分析显示肝损伤发生率较高。多因素分析无统计学意义。
大约47.7%的COVID-19患者在急性感染后6个月内出现持续性ALB，它与BMI升高有关，血清LDL升高，MAFLD和CLD的发生率增加，单因素分析的肝损伤率较高，但不是多变量分析。
■一项针对COVID-19感染住院的成年患者的多中心研究，至少有一次肝功能异常检查，进行了。详细的实验室和成像测试，包括经腹超声和FibroScan,在评估时和出院后6个月随访时进行.
■从1246名住院患者的初始队列中，731（58.7%）患有ALB。共有174/731例患者符合纳入标准，具有以下特征：48.9%的患者患有重度COVID-19；62.1%的患者患有慢性肝病（CLD）；56.9%的患者患有代谢相关脂肪肝（MAFLD）。ALB主要为混合模式(67.8%)。在那些有肝损伤（天冬氨酸转氨酶/丙氨酸转氨酶>正常上限的3倍，（55.2％），或碱性磷酸酶/γ-谷氨酰转移酶/胆红素>正常上限的2倍），混合模式同样占主导地位。在出院后的6个月内，约有52.3％的肝脏结合力测试恢复正常。持续性ALB患者的平均体重指数(BMI)和血清低密度脂蛋白(LDL)显著增高,MAFLD和CLD的发生率更高，FibroScan的平均肝脏硬度测量值和连续衰减参数评分更高，单因素分析显示肝损伤发生率较高。多因素分析无统计学意义。
大约47.7%的COVID-19患者在急性感染后6个月内出现持续性ALB，它与BMI升高有关，血清LDL升高，MAFLD和CLD的发生率增加，单因素分析的肝损伤率较高，但不是多变量分析。
